Division of Hemato-Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
J Korean Med Sci. 2023 Sep 11;38(36):e281. doi: 10.3346/jkms.2023.38.e281.
Allogeneic hematopoietic stem cell transplantation (HSCT) was not actively performed in elderly acute myeloid leukemia (AML) or myelodysplastic syndrome patients who are at a high-risk based on hematopoietic cell transplantation-specific comorbidity index (HCT-CI). The advent of reduced-intensity conditioning (RIC) regimens has made HSCT applicable in this population. However, the selection of appropriate conditioning is a major concern for the attending physician. The benefits of combination of treosulfan and fludarabine (Treo/Flu) have been confirmed through many clinical studies. Korean data on treosulfan-based conditioning regimen are scarce.
A retrospective study was conducted to compare the clinical outcomes of allogeneic HSCT using RIC between 13 patients receiving Treo/Flu and 39 receiving busulfan/fludarabine (Bu/Flu).
In terms of conditioning-related complications, the frequency of ≥ grade 2 nausea or vomiting was significantly lower and the duration of symptoms was shorter in the Treo/Flu group than in the Bu/Flu group. The incidence of ≥ grade 2 mucositis tended to be lower in the Treo/Flu group. In the analysis of transplant outcomes, all events of acute graft versus host disease (GVHD) and ≥ grade 2 acute GVHD occurred more frequently in the Treo/Flu group. The frequency of Epstein-Barr virus reactivation was significantly higher in the Treo/Flu group (53.8% vs. 23.1%, = 0.037). Non-relapse mortality (NRM) at 12 months was higher in the Treo/Flu group (30.8% vs. 7.7%, = 0.035). Significant prognostic factors included disease type, especially secondary AML, disease status and high-risk based on HCT-CI, ≥ grade 2 acute GVHD, and cases requiring ≥ 2 immunosuppressive drugs for treating acute GVHD. In the comparison of survival outcomes according to conditioning regimen, the Bu/Flu group seemed to show better results than the Treo/Flu group (60% vs. 46.2%, = 0.092 for overall survival; 56.4% vs. 38.5%, = 0.193 for relapse-free survival). In additional analysis for only HCT-CI high-risk groups, there was no difference in transplant outcomes except that the Treo/Flu group tended to have a higher NRM within one year after transplantation. Survival outcomes of both groups were similar.
This study suggests that Treo/Flu conditioning may be an alternative to Bu/Flu regimen in elderly patients with high-risk who are not suitable for standard conditioning.
对于基于造血细胞移植特定合并症指数(HCT-CI)的高危老年急性髓系白血病(AML)或骨髓增生异常综合征患者,并未积极进行异基因造血干细胞移植(HSCT)。由于强化预处理(RIC)方案的出现,HSCT 已适用于该人群。然而,对于主治医生来说,选择合适的预处理方案是一个主要关注点。通过许多临床研究已经证实了硼替佐米和氟达拉滨(Treo/Flu)联合的益处。关于基于硼替佐米的预处理方案的韩国数据很少。
对 13 例接受 Treo/Flu 和 39 例接受白消安/氟达拉滨(Bu/Flu)的接受 RIC 的异基因 HSCT 的患者进行回顾性研究,比较其临床结局。
在预处理相关并发症方面,Treo/Flu 组≥2 级恶心或呕吐的频率较低,症状持续时间较短。Treo/Flu 组的≥2 级粘膜炎发生率较低。在移植结局分析中,Treo/Flu 组更常发生急性移植物抗宿主病(GVHD)和≥2 级急性 GVHD。Treo/Flu 组 EBV 再激活的频率明显更高(53.8%比 23.1%,=0.037)。Treo/Flu 组 12 个月时非复发死亡率(NRM)较高(30.8%比 7.7%,=0.035)。显著的预后因素包括疾病类型,特别是继发性 AML;疾病状态和基于 HCT-CI 的高危状态;≥2 级急性 GVHD;以及需要≥2 种免疫抑制剂治疗急性 GVHD 的病例。根据预处理方案比较生存结局时,Bu/Flu 组似乎比 Treo/Flu 组的结果更好(总生存:60%比 46.2%,=0.092;无复发生存:56.4%比 38.5%,=0.193)。在仅对 HCT-CI 高危组的附加分析中,除了 Treo/Flu 组在移植后 1 年内 NRM 较高外,移植结局无差异。两组的生存结局相似。
本研究表明,对于不适合标准预处理的高危老年患者,Treo/Flu 预处理可能是 Bu/Flu 方案的替代方案。